Compounds > pyrazolanthrone
Page last updated: 2024-08-18

pyrazolanthrone and Multiple Myeloma

pyrazolanthrone has been researched along with Multiple Myeloma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jeong, SJ; Jung, JH; Kim, B; Kim, JH; Kim, SH; Lee, HJ; Sohn, EJ; Sook, SH1
Bai, QX; Zhang, XY1
Feng, J; Li, Z; Ma, Y; Wang, Y1
Anderson, KC; Chauhan, D; Hideshima, T; Kharbanda, S; Li, G; Mitsiades, C; Mitsiades, N; Munshi, N; Podar, K1
Akiyama, M; Anderson, K; Chauhan, D; Hayashi, T; Hideshima, T; Richardson, P1

Other Studies

5 other study(ies) available for pyrazolanthrone and Multiple Myeloma

ArticleYear
Reactive oxygen species-mediated activation of AMP-activated protein kinase and c-Jun N-terminal kinase plays a critical role in beta-sitosterol-induced apoptosis in multiple myeloma U266 cells.
    Phytotherapy research : PTR, 2014, Volume: 28, Issue:3

    Topics: Acetyl-CoA Carboxylase; Acetylcysteine; AMP-Activated Protein Kinases; Anthracenes; Apoptosis; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclooxygenase 2; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Multiple Myeloma; Phosphorylation; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Sitosterols

2014
Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK.
    International journal of molecular sciences, 2012, Volume: 13, Issue:4

    Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Curcumin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Pyrazines; Transcription Factor RelA

2012
Brucine induces the apoptosis of U266 multiple myeloma cells by phosphorylation of c-Jun.
    Molecular medicine reports, 2013, Volume: 7, Issue:2

    Topics: Adjuvants, Immunologic; Anthracenes; Apoptosis; Caspase 3; Cell Line, Tumor; G1 Phase Cell Cycle Checkpoints; Humans; JNK Mitogen-Activated Protein Kinases; Multiple Myeloma; Phosphorylation; Signal Transduction; Strychnine

2013
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.
    The Journal of biological chemistry, 2003, May-16, Volume: 278, Issue:20

    Topics: Anthracenes; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Carrier Proteins; Cell Line; Coloring Agents; Cytochrome c Group; Cytosol; DNA, Complementary; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genes, Dominant; Green Fluorescent Proteins; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Luminescent Proteins; MAP Kinase Kinase 4; Membrane Potentials; Mitochondria; Mitochondrial Proteins; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Multiple Myeloma; Serine; Tetrazolium Salts; Thiazoles; Time Factors; Transfection; Tumor Cells, Cultured

2003
Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines.
    Oncogene, 2003, Nov-27, Volume: 22, Issue:54

    Topics: Anthracenes; Cell Line, Tumor; DNA-Binding Proteins; Enzyme Activation; Humans; Insulin-Like Growth Factor I; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Multiple Myeloma; NF-kappa B; Phosphorylation; STAT3 Transcription Factor; Trans-Activators

2003